/Edwards%20Lifesciences%20Corp%20Irvine%2C%20Ca%20campus-by%20Steve%20Cukrov%20via%20Shutterstock.jpg)
Irvine, California-based Edwards Lifesciences Corporation (EW) provides products and technologies to treat advanced cardiovascular diseases in the United States and internationally. With a market cap of $45.3 billion, the company is set to unveil its second-quarter results on Thursday, July 24, after the market closes.
Ahead of the event, analysts expect EW to report non-GAAP earnings of $0.62 per share, down 11.4% from the profit of $0.70 per share reported in the year-ago quarter. Additionally, the company has surpassed or matched the Street’s bottom-line projections in each of the past four quarters, which is impressive.
For the current year, its earnings are expected to come in at $2.46 per share, up 1.2% from $2.43 per share reported in the year-ago quarter. Moreover, in fiscal 2026, its earnings are expected to rise 11.8% year-over-year to $2.75 per share.
EW stock has declined 15.6% over the past 52 weeks, underperforming the Health Care Select Sector SPDR Fund’s (XLV) 6.3% decline and the S&P 500 Index’s ($SPX) 13% uptick during the same time frame.
Shares of Edward Lifesciences rose 6.6% following the release of its Q1 2025 results on Apr. 23. The company’s sales rose 6.2% year-over-year to $1.4 billion, and surpassed the Wall Street estimates. Moreover, its adjusted EPS came in at $0.64, up 16.4% from the same quarter last year and surpassed the consensus estimate by 6.7%.
The consensus opinion on EW is somewhat optimistic, with a “Moderate Buy” rating overall. Of the 29 analysts covering the stock, opinions include 12 “Strong Buys,” one “Moderate Buy,” 15 “Holds,” and one “Strong Sell.” Its mean price target of $80.81 suggests a 4.9% upside potential from current price levels.
